GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rockwell Medical Inc (NAS:RMTI) » Definitions » Free Cash Flow

Rockwell Medical (Rockwell Medical) Free Cash Flow : $-8.19 Mil (TTM As of Mar. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Rockwell Medical Free Cash Flow?

Rockwell Medical's total free cash flow for the months ended in Mar. 2024 was $-2.52 Mil. Its total free cash flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-8.19 Mil.

Rockwell Medical's Free Cash Flow per Share for the months ended in Mar. 2024 was $-0.09. Its free cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.32.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 54.70% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 37.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Free Cash Flow Growth Rate using Free Cash Flow per Share data.

During the past 13 years, Rockwell Medical's highest 3-Year average Free Cash Flow per Share Growth Rate was 54.70% per year. The lowest was -95.20% per year. And the median was 8.95% per year.


Rockwell Medical Free Cash Flow Historical Data

The historical data trend for Rockwell Medical's Free Cash Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rockwell Medical Free Cash Flow Chart

Rockwell Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Free Cash Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only -28.59 -30.69 -34.06 -17.21 -9.70

Rockwell Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Free Cash Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.02 -1.82 -3.77 -0.09 -2.52

Rockwell Medical Free Cash Flow Calculation

Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.

Rockwell Medical's Free Cash Flow for the fiscal year that ended in Dec. 2023 is calculated as

Free Cash Flow (A: Dec. 2023 )=Cash Flow from Operations+Capital Expenditure
=-9.412+-0.284
=-9.70

Rockwell Medical's Free Cash Flow for the quarter that ended in Mar. 2024 is calculated as

Free Cash Flow (Q: Mar. 2024 )=Cash Flow from Operations+Capital Expenditure
=-2.38+-0.139
=-2.52

Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rockwell Medical  (NAS:RMTI) Free Cash Flow Explanation

Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.

In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.

This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over seven years. The reason we use seven years is because research shows that seven years is the length of the typical business cycle.

Therefore, as of Mar24, Rockwell Medical's Forward Rate of Return (Yacktman) % is

Forward Rate of Return (Yacktman) % (Mar24)=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/1.66+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.


Rockwell Medical Free Cash Flow Related Terms

Thank you for viewing the detailed overview of Rockwell Medical's Free Cash Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Rockwell Medical (Rockwell Medical) Business Description

Traded in Other Exchanges
Address
30142 S. Wixom Road, Wixom, MI, USA, 48393
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. Rockwell Medical's mission is to provide dialysis clinics and patients with the highest quality products supported by the best customer service in the industry. It is focused on innovative, long-term growth strategies that enhance products, processes, and people, enabling the company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients.
Executives
Jesse Neri officer: SVP, FINANCE 851 DUPORTAIL ROAD, SECOND FLOOR, CHESTERBROOK PA 19087
Joan Lau director C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Russell Skibsted officer: See Remarks 15 TRANQUILITY PLACE, LADERA RANCH CA 92694
Megan C. Timmins officer: SVP, General Counsel 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Mark Strobeck director, officer: President and CEO 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Allen Nissenson director 601 HAWAII ST., EL SEGUNDO CA 90245
Robert S Radie director 101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355
Andrea Heslin Smiley director 600 LEE ROAD, SUITE 100, WAYNE PA 19087
David S. Richmond 10 percent owner, other: See Footnote 1 3568 WILDWOOD AVENUE, JACKSON MI 49202
Russell H Ellison director 270 RIVERSIDE DR., APT. 12D, NEW YORK NY 10025
Marc L Hoffman officer: Chief Medical Officer 30142 WIXOM ROAD, WIXOM MI 48393
John Peter Mclaughlin director C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE NV 89451
Richmond Brothers, Inc. 10 percent owner, other: See Footnote 1 7415 FOXWORTH COURT, JACKSON MI 49201
Stuart M Paul director, officer: Chief Executive Officer HOME DIAGNOSTICS, INC., 2400 NW 55TH COURT, FORT LAUDERDALE FL 33309
Angus W. Smith officer: Chief Financial Officer C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960